Transarterial Chemoembolization (TACE)
Treatment for Liver cancer due to alcohol use
Effectiveness
70%
Safety Score
65%
Clinical Trials
100
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Time to Effect
Clinical benefit seen within weeks to months
Treatment Duration
Repeated every 1-3 months for several cycles
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$45,000
Side Effect Mgmt:$5,000
Total Annual:$50,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.75
Outcome-Based Costs
Cost per Responder
$90,909
Cost per Remission
$250,000
Transarterial Chemoembolization (TACE) Outcomes
for Liver cancer due to alcohol use
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Remission Rate
+20%
Common Side Effects
Post-embolization syndrome (fever, pain, nausea)
+70%
Liver function abnormalities
+40%
Fatigue
+35%
Infection
+3%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov